123 related articles for article (PubMed ID: 17679484)
21. Targeting methylguanine-DNA methyltransferase in the treatment of neuroblastoma.
Wagner LM; McLendon RE; Yoon KJ; Weiss BD; Billups CA; Danks MK
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5418-25. PubMed ID: 17875772
[TBL] [Abstract][Full Text] [Related]
22. Focus on Fotemustine.
De Rossi A; Rossi L; Laudisi A; Sini V; Toppo L; Marchesi F; Tortorelli G; Leti M; Turriziani M; Aquino A; Bonmassar E; De Vecchis L; Torino F
J Exp Clin Cancer Res; 2006 Dec; 25(4):461-8. PubMed ID: 17310834
[TBL] [Abstract][Full Text] [Related]
23. [Significant regression of glioblastoma with low level of Mgmt gene expression following radiotherapy].
Matsko MV; Luchin EI; Ievleva AG; Bakholdin DV; Abysheva SN; Zavgorodniaia EV; Potapova ON; Imianitov EN; Ulitin AIu; Matsko DE
Vopr Onkol; 2011; 57(2):245-9. PubMed ID: 21809674
[TBL] [Abstract][Full Text] [Related]
24. Prime time for molecular marker diagnostics in neuro-oncology.
Weller M; Stupp R
Curr Opin Neurol; 2012 Dec; 25(6):743-4. PubMed ID: 23041956
[No Abstract] [Full Text] [Related]
25. Prognostic and predictive roles of MGMT protein expression and promoter methylation in sporadic pancreatic neuroendocrine neoplasms.
Schmitt AM; Pavel M; Rudolph T; Dawson H; Blank A; Komminoth P; Vassella E; Perren A
Neuroendocrinology; 2014; 100(1):35-44. PubMed ID: 25012122
[TBL] [Abstract][Full Text] [Related]
26. Resveratrol reverses temozolomide resistance by downregulation of MGMT in T98G glioblastoma cells by the NF-κB-dependent pathway.
Huang H; Lin H; Zhang X; Li J
Oncol Rep; 2012 Jun; 27(6):2050-6. PubMed ID: 22426504
[TBL] [Abstract][Full Text] [Related]
27. O6-benzylguanine: a clinical trial establishing the biochemical modulatory dose in tumor tissue for alkyltransferase-directed DNA repair.
Spiro TP; Gerson SL; Liu L; Majka S; Haaga J; Hoppel CL; Ingalls ST; Pluda JM; Willson JK
Cancer Res; 1999 May; 59(10):2402-10. PubMed ID: 10344750
[TBL] [Abstract][Full Text] [Related]
28. Investigating a signature of temozolomide resistance in GBM cell lines using metabolomics.
St-Coeur PD; Poitras JJ; Cuperlovic-Culf M; Touaibia M; Morin P
J Neurooncol; 2015 Oct; 125(1):91-102. PubMed ID: 26311249
[TBL] [Abstract][Full Text] [Related]
29. MGMT methylation in glioblastoma: tale of the tail.
Shah N; Schroeder B; Cobbs C
Neuro Oncol; 2015 Jan; 17(1):167-8. PubMed ID: 25395464
[No Abstract] [Full Text] [Related]
30. DNA mismatch repair protein (MSH6) correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide: the national cooperative study by the Japan Society for Hypothalamic and Pituitary Tumors.
Hirohata T; Asano K; Ogawa Y; Takano S; Amano K; Isozaki O; Iwai Y; Sakata K; Fukuhara N; Nishioka H; Yamada S; Fujio S; Arita K; Takano K; Tominaga A; Hizuka N; Ikeda H; Osamura RY; Tahara S; Ishii Y; Kawamata T; Shimatsu A; Teramoto A; Matsuno A
J Clin Endocrinol Metab; 2013 Mar; 98(3):1130-6. PubMed ID: 23365123
[TBL] [Abstract][Full Text] [Related]
31. Novel role of triazenes in haematological malignancies: pilot study of Temozolomide, Lomeguatrib and IL-2 in the chemo-immunotherapy of acute leukaemia.
Caporaso P; Turriziani M; Venditti A; Marchesi F; Buccisano F; Tirindelli MC; Alvino E; Garbin A; Tortorelli G; Toppo L; Bonmassar E; D'Atri S; Amadori S
DNA Repair (Amst); 2007 Aug; 6(8):1179-86. PubMed ID: 17500047
[TBL] [Abstract][Full Text] [Related]
32. Structure-based design of nitrosoureas containing tyrosine derivatives as potential antimelanoma agents.
Gadjeva V
Eur J Med Chem; 2002 Apr; 37(4):295-300. PubMed ID: 11960664
[TBL] [Abstract][Full Text] [Related]
33. Impact of Therapy Sequence with Alkylating Agents and MGMT Status in Patients with Advanced Neuroendocrine Tumors.
Krug S; Boch M; Rexin P; Gress TM; Michl P; Rinke A
Anticancer Res; 2017 May; 37(5):2491-2500. PubMed ID: 28476818
[TBL] [Abstract][Full Text] [Related]
34. JNK contributes to temozolomide resistance of stem-like glioblastoma cells via regulation of MGMT expression.
Okada M; Sato A; Shibuya K; Watanabe E; Seino S; Suzuki S; Seino M; Narita Y; Shibui S; Kayama T; Kitanaka C
Int J Oncol; 2014 Feb; 44(2):591-9. PubMed ID: 24316756
[TBL] [Abstract][Full Text] [Related]
35. [Strategy for studying gene methylation: the example of MGMT].
Fina F; Nanni-Metellus I; Courdy C; Figarella-Branger D; Martin PM; Ouafik L
Ann Pathol; 2009 Nov; 29 Spec No 1():S37-9. PubMed ID: 19887248
[No Abstract] [Full Text] [Related]
36. MGMT expression levels predict disease stabilisation, progression-free and overall survival in patients with advanced melanomas treated with DTIC.
Busch C; Geisler J; Lillehaug JR; Lønning PE
Eur J Cancer; 2010 Jul; 46(11):2127-33. PubMed ID: 20541396
[TBL] [Abstract][Full Text] [Related]
37. The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide.
Rapkins RW; Wang F; Nguyen HN; Cloughesy TF; Lai A; Ha W; Nowak AK; Hitchins MP; McDonald KL
Neuro Oncol; 2015 Dec; 17(12):1589-98. PubMed ID: 25910840
[TBL] [Abstract][Full Text] [Related]
38. The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials.
Binabaj MM; Bahrami A; ShahidSales S; Joodi M; Joudi Mashhad M; Hassanian SM; Anvari K; Avan A
J Cell Physiol; 2018 Jan; 233(1):378-386. PubMed ID: 28266716
[TBL] [Abstract][Full Text] [Related]
39. The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas.
Cao VT; Jung TY; Jung S; Jin SG; Moon KS; Kim IY; Kang SS; Park CS; Lee KH; Chae HJ
Neurosurgery; 2009 Nov; 65(5):866-75; discussion 875. PubMed ID: 19834398
[TBL] [Abstract][Full Text] [Related]
40. The clinical pharmacology of alkylating agents in high-dose chemotherapy.
Huitema AD; Smits KD; Mathôt RA; Schellens JH; Rodenhuis S; Beijnen JH
Anticancer Drugs; 2000 Aug; 11(7):515-33. PubMed ID: 11036954
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
